Siemens Healthineers AG (WBO:SHL) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:SHL Siemens Healthineers AG WBO:SHL
72 GF Score
Price €35.52
GF Value €52.37
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Siemens Healthineers AG Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WBO:SHL
72GF Score
Siemens Healthineers AG WBO:SHL
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Siemens Healthineers AG (WBO:SHL) Overvalued in 2026?

Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued. The current stock price of €35.52 is trading 32.2% below its estimated GF Value™ of €52.37. GuruFocus considers Siemens Healthineers AG to be Possible Value Trap.

Key valuation signals for WBO:SHL:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €52.37 vs. price of €35.52 (32.2% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the WBO:SHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Siemens Healthineers AG Business Description

Address Siemensstrasse 3, Forchheim, BY, DEU, 91301
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
72GF Score

Get the complete analysis for WBO:SHL

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.52
Price
€52.37
GF Value